Abstract
BackgroundPrevious study demonstrated that miR-133a was released into blood from injured myocardium in cardiovascular diseases. However, the dynamic change of circulating miR-133a level in the early phase of acute myocardial infarction (AMI) and the correlation between miR-133a and severity of coronary stenosis in coronary heart disease (CHD) patients are not clear.Methods and resultsThree different cohorts (including 13 AMI patients, 176 angina pectoris patients and 127 control subjects) were enrolled to investigate the expression levels of circulating miR-133a in patients with myocardial ischemia and also the relationship between plasma miR-133a and severity of coronary stenosis. Plasma miR-133a levels of participants were examined by real-time quantitative PCR. Simultaneously, plasma cardiac troponin I (cTnI) concentrations were measured by ELISA assays. The results showed that circulating miR-133a level was significantly increased in AMI patients in time-dependent manner, and achieved a 72.1 fold peak at 21.6 ± 4.5 hours after the onset of AMI symptoms and exhibited a similar trend to plasma cTnI level. We also found that plasma miR-133a levels were higher in CHD patients than control group. Importantly, the levels of circulating miR-133a positively correlated with the severities of the coronary artery stenosis. Receiver operating characteristic (ROC) analysis revealed that circulating miR-133a had considerable diagnostic accuracy for CHD with an AUC of 0.918 (95% confidence interval 0.877-0.960).ConclusionsCirculating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And increased miR-133a level may be used to predict both the presence and severity of coronary lesions in CHD patients.
Highlights
Acute myocardial infarction (AMI) is the worst acute syndrome of coronary heart diseases (CHD) with high morbidity and mortality
These studies demonstrated that the expression of circulating miR-133a increased in patients with CHD and circulating miR-133a can be used as a marker for cardiomyocyte death, few clinical studies have reported on the dynamic change in circulating miR133a level in the early phase of acute myocardial infarction (AMI), and the correlation between miR-133a concentration and the severity of coronary stenosis in CHD patients is not clear
The pattern of plasma miR-133a levels in acute myocardial infarction Firstly, 13 AMI patients and 27 healthy volunteers were selected in the first cohort to test whether circulating miR-133a could serve as a novel biomarker of AMI
Summary
Acute myocardial infarction (AMI) is the worst acute syndrome of coronary heart diseases (CHD) with high morbidity and mortality. It has been reported that the elevated miR-133a is released into peripheral circulation from the injured myocardium after Ca2+ stimulation [25] These studies demonstrated that the expression of circulating miR-133a increased in patients with CHD (including AMI and angina pectoris) and circulating miR-133a can be used as a marker for cardiomyocyte death, few clinical studies have reported on the dynamic change in circulating miR133a level in the early phase of AMI, and the correlation between miR-133a concentration and the severity of coronary stenosis in CHD patients is not clear. The dynamic change of circulating miR-133a level in the early phase of acute myocardial infarction (AMI) and the correlation between miR-133a and severity of coronary stenosis in coronary heart disease (CHD) patients are not clear
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
